All News
EULAR 2022 – Day 4 Report
Bags are packed, ready to go, but wait there’s more abstracts to show.
The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased.
Read Article
Topical therapies take centre stage
Topical treatments have so often been the low level “sure you can try this” option. However there are exciting data that these approaches may become part of our main armamentarium.
Read Article
EULAR 2022 – Day 3 Report
By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
Read Article
Watch: #EULAR2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
https://t.co/B7AYkTnAe0 https://t.co/NF3f6AFv6K
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2022 – Day 4 Report
Check out our my favorite late-breakers from Day 4.
https://t.co/R0hPetOos4 https://t.co/T57XRIKZs5
Links:
Dr. John Cush RheumNow ( View Tweet)
WATCH: #EULAR2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
https://t.co/ExCXY6Xbl4
@Janetbirdope @AurelieRheumo @Yuz6Yusof https://t.co/tIB8QrdYuI
Links:
Dr. John Cush RheumNow ( View Tweet)
MIVAC I & II RCTs from India:
for AZ vaccine (ChAdOx1), withhold MTX for 2w after:
hold both dose 1&2
or hold just dose 2
(vs continue)
Endpoint: Ab titre
both hold approaches better than continue, to a similar magnitude
- similar to German study w mRNA
#EULAR2022 @RheumNow
David Liew drdavidliew ( View Tweet)
#LB0006 #EULAR2022 Therapy for relapsing polymyalgia rheumatica. 118/280 recruited re:COVID impact. Phase 3 RCT of Sarilumab+14Wk Steroid taper showed more pts had sustained remission at Wk52 vs PBO+52Wk Steroid Taper(28% vs 10%) even if CRP excluded. PRO improved too! @RheumNow https://t.co/P11iXIAfGn
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Novel ePROMS use. Use of ePROMS RAPID3/PASS and asking patients if they had a flare had high diagnostic accuracy identifying those not needing DMARD or steroid intensification up and eligible to skip their next outpatient clinic visit. Seppen et al #EULAR2022 @RheumNow POS0381
Dr. Antoni Chan synovialjoints ( View Tweet)
Who remotely enters PROs online? Glintborg et al from the Danbio Registry showed that patients who used the system were mainly 40-80 years of age, on biologics and had lower HAQ score. Disease duration and diagnosis had no impact, reminders helped #EULAR2022 @RheumNow POS0373 https://t.co/voCfGiJgwm
Dr. Antoni Chan synovialjoints ( View Tweet)
#POS1112 #EULAR2022 A crossover RCT assessed effect of weight- and non-weight bearing exercises on type 2 collagen in knee #osteoarthritis. Small rise in collagen turnover markers initially for 24hrs. Gradual rise later on was contributed to cardiovascular influence @RheumNow https://t.co/AOxdFNihPR
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The potential for patients to benefit from digital health technologies in rheumatology is multifaceted, upside might be enormous.
There's so much space for us all, but there are factors in many domains where it can all go wrong.
We need to raise standards.
#EULAR2022 @RheumNow https://t.co/TozfK1Qs16
David Liew drdavidliew ( View Tweet)
Agree. Love to understand:
- standardisation for whole body MRI
- how it does not compromise image quality vs limited field
- clear explanation of benefit vs limited field, where it exists
Its inappropriate use in the worried well by charlatans has skewed me #EULAR2022 @RheumNow https://t.co/3LRz0OOAEF
David Liew drdavidliew ( View Tweet)
Sousa et al. Anti-Ku disease. Cluster analysis (Ku alone, Ku with other abs) asking is is a distinct entity. In isolated anti-Ku+ maybe so, characterised by Raynauds (41%), arthritis (26%), sicca (26%), myositis (15%), ILD (15%) @RheumNow #EULAR2022 POS0861 https://t.co/IboWzMYFMB
Richard Conway RichardPAConway ( View Tweet)
#OP0286 #EULAR2022 With no licensed therapy, we need a better and responsive outcome measure. Using data-driven method, SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR) has been developed. This will be evaluated in NECESSITY RCTs across Europe @RheumNow https://t.co/U5Aj6bwWBy
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
So maybe, when it comes to delivering healthcare and telemedicine, we need to think about quality and efficiency? #EULAR2022 @RheumNow https://t.co/JMbQ1ZUB0o
David Liew drdavidliew ( View Tweet)
and, Robert Landewe argues, telemedicine is merely exchanging parcels of information.
Life visits deliver the chance for empathy #EULAR2022 @RheumNow https://t.co/2CKTJHfF7A
David Liew drdavidliew ( View Tweet)
Quality patient communication is actually critical to outcome #EULAR2022 @RheumNow https://t.co/37Z7hwrWmX
David Liew drdavidliew ( View Tweet)
What's the argument against that?
Fundamentally, empathy. The patient experience isn't just a product of miracle drugs - over time it's a multitude of factors that are what leads to happy patients
#EULAR2022 @RheumNow https://t.co/8GwhdT8cit
David Liew drdavidliew ( View Tweet)
and if we don't act, we leave it to the wild, wild west of the private market:
- designed for profit (not necessarily bad)
- but often at the cost of robust dedication to patient outcomes (always bad)
#EULAR2022 @RheumNow https://t.co/zfJWTZ3I1G
David Liew drdavidliew ( View Tweet)
